


Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) A compound of Formula VIII:

wherein:



FORMULA VIII

Z is selected from the group consisting of $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}(\text{CH}_3)-$, $-\text{CH}=\text{CH}-$, $-\text{O}-\text{CH}_2-$, $-\text{S}-\text{CH}_2-$, $-\text{O}-$, and $-\text{S}-$;

X^1 and X^2 are independently selected from the group consisting of $-\text{F}$, $-\text{CH}_3$, $-\text{OH}$, and lower O-alkyl in the 1-, 3-, 7-, or 9-substituent positions;

m can be 1 or 2;

$-\text{NHR}$ is selected from the group consisting of $-\text{NH}_2$, $-\text{NHCH}_3$, and $-\text{NHC}_2\text{H}_5$;

R^1 is selected from the group consisting of $-\text{H}$, alkyl, hydroxyalkyl, $-\text{OH}$, $-\text{O-alkyl}$, and $-\text{O-acyl}$, and

Atty. Dkt. No. 072827-0372

R^2 is selected from the group consisting of -H, alkyl, hydroxyalkyl, and pharmaceutically acceptable salts and complexes thereof, wherein the compound is active at an NMDA receptor.

2. (New) The compound of claim 1, wherein R^1 and R^2 are independently selected from the group consisting of -H and alkyl.

3. (New) The compound of claim 1, wherein Z is selected from the group consisting of -CH₂CH₂-, -CH=CH-, -O-CH₂-, -O-, and -S-.

4. (New) The compound of claim 1, wherein Z is selected from the group consisting of -CH₂CH₂-, and -O-CH₂-.

5. (New) The compound of claim 2, wherein Z is selected from the group consisting of -CH₂CH₂-, -CH=CH-, -O-CH₂-, -O-, and -S-.

6. (New) The compound of claim 2, wherein Z is selected from the group consisting of -CH₂CH₂-, and -O-CH₂-.